KR100319397B1 - 천연식물소재 추출물을 이용한 항혈전 및 고지혈증 억제 조성물 - Google Patents
천연식물소재 추출물을 이용한 항혈전 및 고지혈증 억제 조성물 Download PDFInfo
- Publication number
- KR100319397B1 KR100319397B1 KR1019990028024A KR19990028024A KR100319397B1 KR 100319397 B1 KR100319397 B1 KR 100319397B1 KR 1019990028024 A KR1019990028024 A KR 1019990028024A KR 19990028024 A KR19990028024 A KR 19990028024A KR 100319397 B1 KR100319397 B1 KR 100319397B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- activity
- weight
- cholesterol
- blood
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 37
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 27
- 239000004480 active ingredient Substances 0.000 title claims description 10
- 239000000419 plant extract Substances 0.000 title description 17
- 239000000284 extract Substances 0.000 claims abstract description 49
- 239000000463 material Substances 0.000 claims abstract description 35
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 31
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000196324 Embryophyta Species 0.000 claims description 24
- 244000068988 Glycine max Species 0.000 claims description 16
- 235000010469 Glycine max Nutrition 0.000 claims description 15
- 244000269722 Thea sinensis Species 0.000 claims description 13
- 240000008397 Ganoderma lucidum Species 0.000 claims description 8
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 8
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 8
- 235000006468 Thea sinensis Nutrition 0.000 claims description 7
- 235000020279 black tea Nutrition 0.000 claims description 7
- 235000002532 grape seed extract Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 5
- 241000282374 Puma concolor Species 0.000 claims description 5
- 235000009569 green tea Nutrition 0.000 claims description 5
- 240000006365 Vitis vinifera Species 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 229940087559 grape seed Drugs 0.000 claims description 4
- 240000008142 Crambe tatarica Species 0.000 claims description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 229940111260 ginkgo folium Drugs 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 229940102480 bilberry extract Drugs 0.000 claims 2
- 235000019209 bilberry extract Nutrition 0.000 claims 2
- 229940087603 grape seed extract Drugs 0.000 claims 2
- 229940094952 green tea extract Drugs 0.000 claims 2
- 235000020688 green tea extract Nutrition 0.000 claims 2
- 239000001717 vitis vinifera seed extract Substances 0.000 claims 2
- 235000011201 Ginkgo Nutrition 0.000 claims 1
- 241000218628 Ginkgo Species 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 66
- 230000000694 effects Effects 0.000 abstract description 52
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 29
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 230000023555 blood coagulation Effects 0.000 abstract description 26
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 11
- 230000002537 thrombolytic effect Effects 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 8
- 238000012216 screening Methods 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000011149 active material Substances 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 description 18
- 230000008859 change Effects 0.000 description 17
- 208000031226 Hyperlipidaemia Diseases 0.000 description 13
- 230000015271 coagulation Effects 0.000 description 12
- 238000005345 coagulation Methods 0.000 description 12
- 108010023302 HDL Cholesterol Proteins 0.000 description 11
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 238000008214 LDL Cholesterol Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- 229960001138 acetylsalicylic acid Drugs 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 206010003210 Arteriosclerosis Diseases 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 150000001840 cholesterol esters Chemical class 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 240000002234 Allium sativum Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 244000241872 Lycium chinense Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 235000004611 garlic Nutrition 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000005255 Allium cepa Nutrition 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000003910 Baronia <angiosperm> Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000014105 formulated food Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 240000004487 Cynoglossum officinale Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241001608711 Melo Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K11/00—Multiple-way valves, e.g. mixing valves; Pipe fittings incorporating such valves
- F16K11/10—Multiple-way valves, e.g. mixing valves; Pipe fittings incorporating such valves with two or more closure members not moving as a unit
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K17/00—Safety valves; Equalising valves, e.g. pressure relief valves
- F16K17/02—Safety valves; Equalising valves, e.g. pressure relief valves opening on surplus pressure on one side; closing on insufficient pressure on one side
- F16K17/04—Safety valves; Equalising valves, e.g. pressure relief valves opening on surplus pressure on one side; closing on insufficient pressure on one side spring-loaded
- F16K17/0473—Multiple-way safety valves
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K27/00—Construction of housing; Use of materials therefor
- F16K27/02—Construction of housing; Use of materials therefor of lift valves
- F16K27/0263—Construction of housing; Use of materials therefor of lift valves multiple way valves
Landscapes
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
추출물 | 천연식물 | 혈액응고억제 | 혈전용해a | 혈소판응집억제 |
영지(Ganoderma)은행잎(Gingko)산사자(Crataegus)녹차(Green tea)홍차(Black tea)포도씨(Grape seed)빌베리(Billberry)마늘(Garlic)양파(Onion)건칠(Rhus)목단피(Paeonica)구기자(Lycium)오미자(Schizandra)인삼(Ginseng)과채(Cumunic)천궁(Cinidium)대두발효추출물(Fermented soybean)대두유래 플라보노이드(Soybean flavonoids) | G. lucidum Gingko folium C. pinnatifida Camelliae sinensis Theae sinensis Vitis vinifera Vaccinium myrtillus Allium sativum Allium cepa R. vernicifula P. suffutica L. chinensis S. chinensis Panax ginseng C. melo C. officinale Glycine max Glycine max | -++++++++++++++++++------- | +++++(+)+++++++++++++----++--+++++ | ++(+)-+++++++++++--n.d.n.d.n.d.n.d.n.d.n.d.n.d.+(+)+ |
성 분 명 | 효과적 성분비 | 최적성분비 | 제 형 |
영지(G. lucidum) 추출물녹차(Camelliae sinensis) 추출물홍차(Theae sinensis) 추출물산사자(C. pinnatifida) 추출물포도씨(Vitis vinifera) 추출물은행잎(Ginkgo folium) 추출물대두(Glycine max)발효추출물빌베리(Vaccinium myrtillus) 추출물 | 20-505-305-305-305-300.5-50.5-51-10 | 321912.51612.51.61.64.8 | 분말분말분말분말분말분말분말분말 |
총 계 | 100 |
분석처리군 | 혈소판 응집억제 | 전혈응고시간(초) | 혈장응고시간(초) | 출혈시간(초) | |
(Ω) | () | ||||
정상군(0.5CMC) | 1.5 ± 0.5 | 6.1 ± 1.2 | 49.8 ± 10 | 16.9 ± 7 | 66.6 ± 10 |
대조군(아스피린 투여) | 3.8 ± 0.6 | 17.2 ± 3.1 | 167 ± 10 | 57.5 ± 6 | 163.3 ± 7 |
투여군(Thrombo-QTM) | 3.5 ± 0.7 | 16.3 ± 4.5 | 156.3 ± 8 | 42.8 ± 4 | 155.4 ±5 |
성분 | 함량() |
설탕 | 65 |
비타민 비함유 카제인 | 15 |
AIN-76 무기물 혼합물 | 3.5 |
AIN-76 비타민 혼합물 | 1 |
옥수수유 | 2 |
라아드(Lard) | 8 |
콜레스테롤 | 1 |
염화콜린(Choline chloride) | 0.05 |
알파셀(Alphacel) | 4.45 |
총 합 | 100 |
분석처리군 | 총-콜레스테롤 | 유리-콜레스테롤 | 콜레스테롤에스테르 | HDL-콜레스테롤 | LDL-콜레스테롤 | HDL/LDL 구성비 | 동맥경화지수 | 트리글리세라이드 |
정상군 | 86.4± 12 | 22.4± 3 | 64± 8 | 18.1± 4.7 | 11.7± 5 | 1.499± 0.2 | 3.82± 0.5 | 46.6±5 |
대조군(고지혈증유발식이섬유) | 205.6 ± 22 | 23.2± 5 | 182.4± 27 | 8.8± 2 | 73.7± 12 | 0.128± 0.01 | 26.8± 2 | 74±7 |
투여군(Thrombo-Q) | 151.5 ± 17 | 21.8± 2 | 134± 22 | 9.7± 4 | 54.5± 14 | 0.215± 0.01 | 14.8± 2.5 | 64±2 |
Claims (3)
- 영지(G. lucidum), 녹차(Camelliae sinensis), 홍차(Theae sinensis), 산사자(C. pinnatifida), 포도씨(Vitis vinifera), 은행잎(Ginkgo folium) 및 빌베리(Vaccinium myrtillus)를 각각 10ml/g의 비율로 각각 별개의 증류수에 침지하고, 90℃에서 2시간 동안 역류하여 추출한 다음, 건조시킨 각각의 추출물과 대두(Glycine max) 발효추출물의 천연식물소재 추출혼합물을 유효성분으로 하고, 약학적으로 허용되는 담체를 포함하는 항혈전 및 고지혈증 억제 조성물.
- 제 1항에 있어서,천연식물소재 추출혼합물은 영지 추출물 20 내지 50 중량, 녹차 추출물 5 내지 30 중량, 홍차 추출물 5 내지 30 중량, 산사자 추출물 5 내지 30 중량, 포도씨 추출물 5 내지 30 중량, 은행잎 추출물 0.5 내지 5 중량, 대두발효 추출물 0.5 내지 5 중량및 빌베리 추출물 1 내지 10 중량를 함유하는 것을 특징으로 하는항혈전 및 고지혈증 억제 조성물.
- 영지 추출물 20 내지 50 중량, 녹차 추출물 5 내지 30 중량, 홍차 추출물 5 내지 30 중량, 산사자 추출물 5 내지 30 중량, 포도씨 추출물 5 내지 30 중량, 은행잎 추출물 0.5 내지 5 중량, 대두발효 추출물 0.5 내지 5 중량및 빌베리 추출물1 내지 10 중량를 함유하는 유효성분 100부에 대하여, 담체로서 어유(fish oil) 또는 대두유(soybean oil) 100 내지 200부; 왁스 5 내지 20부; 비타민 P 0.5부 내지 2부; 및, 니아신(niacin) 0.5 내지 2부를 추가로 포함하는 항혈전 및 고지혈증 억제 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990028024A KR100319397B1 (ko) | 1999-07-12 | 1999-07-12 | 천연식물소재 추출물을 이용한 항혈전 및 고지혈증 억제 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990028024A KR100319397B1 (ko) | 1999-07-12 | 1999-07-12 | 천연식물소재 추출물을 이용한 항혈전 및 고지혈증 억제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010009590A KR20010009590A (ko) | 2001-02-05 |
KR100319397B1 true KR100319397B1 (ko) | 2002-01-05 |
Family
ID=19601071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990028024A KR100319397B1 (ko) | 1999-07-12 | 1999-07-12 | 천연식물소재 추출물을 이용한 항혈전 및 고지혈증 억제 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100319397B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100496622B1 (ko) * | 2002-04-29 | 2005-06-29 | (주) 김형민한약연구소 | 비만 억제를 위한 알콜 발효 식품 또는 약학적 조성물 및그의 제조방법 |
KR101575448B1 (ko) | 2014-02-06 | 2015-12-09 | 건양대학교산학협력단 | 항혈전 효과를 갖는 홍차 추출물의 제조방법 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100419451B1 (ko) * | 2000-10-09 | 2004-03-11 | 드림바이오젠 주식회사 | 천연물로부터 유래한 혈전용해 단백질 |
US20030203854A1 (en) * | 2002-04-23 | 2003-10-30 | Ivo Pischel | Composition for effecting serum cholesterol levels |
KR20040030376A (ko) * | 2002-10-02 | 2004-04-09 | 천연제약 주식회사 | 혈전 치료용 약제 조성물 |
PL2218342T3 (pl) * | 2003-05-27 | 2019-01-31 | Dsm Ip Assets B.V. | Nowe kompozycje nutraceutyczne i ich zastosowanie |
ITMI20031313A1 (it) | 2003-06-27 | 2004-12-28 | Indena Spa | Associazioni di agenti vasoprotettori e formulazioni che li contengono. |
KR100733984B1 (ko) * | 2004-07-19 | 2007-06-29 | 이동웅 | 한약재와 곤약을 이용한 비만 또는 고지혈증의 치료 및 예방용 약제학적 조성물 |
KR100656241B1 (ko) * | 2004-09-10 | 2006-12-11 | 롯데제과주식회사 | 고지혈증 및 혈소판 응집에 대해 억제작용을 갖는대두발효 추출물과 이를 이용한 조성물 |
KR101797993B1 (ko) * | 2017-06-09 | 2017-12-12 | 조전호 | 버드나무 변이종의 생약 성분을 포함하는 심혈관계 질환의 치료, 예방 또는 개선용 조성물 |
-
1999
- 1999-07-12 KR KR1019990028024A patent/KR100319397B1/ko not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100496622B1 (ko) * | 2002-04-29 | 2005-06-29 | (주) 김형민한약연구소 | 비만 억제를 위한 알콜 발효 식품 또는 약학적 조성물 및그의 제조방법 |
KR101575448B1 (ko) | 2014-02-06 | 2015-12-09 | 건양대학교산학협력단 | 항혈전 효과를 갖는 홍차 추출물의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20010009590A (ko) | 2001-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Egunyomi et al. | Antisickling activities of two ethnomedicinal plant recipes used for the management of sickle cell anaemia in Ibadan, Nigeria | |
US9295703B2 (en) | Compositions and methods using pomegranate extracts | |
Nevin et al. | Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation | |
US20060040911A1 (en) | Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) | |
US8637098B2 (en) | Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tea containing the same as active ingredient and method for preparing the natural tea | |
Hasona et al. | Ameliorative properties of Iranian Trigonella foenum-graecum L. seeds and Punica granatum L. peel extracts in streptozotocin-induced experimental diabetic guinea pigs | |
US6991811B1 (en) | Echinacea induction of phase II enzymes | |
KR100319397B1 (ko) | 천연식물소재 추출물을 이용한 항혈전 및 고지혈증 억제 조성물 | |
KR20110087965A (ko) | 생맥산 추출물과 그 추출물을 이용한 생맥산 두부 및 그 제조방법 | |
KR20190047865A (ko) | 꾸지뽕 열매 추출물 유래의 혈행개선 조성물 | |
KR20050076104A (ko) | 심혈관계 질환 개선 조성물 | |
Shih et al. | Scavenging of reactive oxygen species and inhibition of the oxidation of low density lipoprotein by the aqueous extraction of Anoectochilus formosanus | |
Akinyede et al. | Antioxidant activity and blood glucose reduction potential of Malabar Chestnut in Streptozotocin Induced Diabetic Rats | |
KR101385191B1 (ko) | 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도 | |
KR100416650B1 (ko) | 둥굴레 추출물과 그를 함유한 혈장 지질 및 혈당 강하용조성물 | |
KR20120016960A (ko) | 다시마를 유효성분으로 함유하는 비만 또는 고지혈증 및 동맥경화성 혈관계 질환의 예방 및 치료용 조성물 | |
KR100970826B1 (ko) | 복합 생약 추출물을 유효성분 함유하는 혈관질환 예방 및치료용 조성물 | |
Enechi et al. | Phytochemical Composition and Anti-Inflammatory Potential of Flavonoid-Rich Fraction of Erythrina senegalensis DC (Fabaceae) Leaf. | |
Bassey Etim et al. | Ameliorative Effect of Aqueous Extract of Tetracarpidium Conophorum (African Walnut on Salt Induced Hypertensive Wistar Rats | |
KR100452128B1 (ko) | 지구자 열매의 활성 성분인 호베노둘리놀, 그의 제조 방법, 및 그를 함유하는 숙취해소를 위한 기능성식품 | |
KR20050032927A (ko) | 청국장 또는 그 추출물을 함유한 지질대사 개선용 조성물 | |
WO2002000234A1 (fr) | Preparation pharmaceutique pour remede traditionnel chinois pour le traitement preventif de maladies cardio-vasculaires et cerebrovasculaires et son procede de preparation | |
KR100603737B1 (ko) | 고추냉이를 함유하는 김치 및 그 제조 방법 | |
Iba et al. | Potentials of ethnobotanicals and nutraceuticals in the management of sickle cell | |
Iba et al. | Potentials of ethnobotanicals and nutraceuticals in the management of sickle cell disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20121012 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20131011 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20141007 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20151007 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20161007 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20171019 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20181010 Year of fee payment: 18 |
|
EXPY | Expiration of term |